Literature DB >> 16918322

Chloroquine resistance reversal agents as promising antimalarial drugs.

Maud Henry1, Sandrine Alibert, Eve Orlandi-Pradines, Hervé Bogreau, Thierry Fusai, Christophe Rogier, Jacques Barbe, Bruno Pradines.   

Abstract

The development and spread of resistance to antimalarial drugs poses a severe and increasing public health threat. Failures of prophylaxis or treatment with quinolines, hydroxynaphthoquinones, sesquiterpene lactones, antifolate drugs and sulfamides are involved in a return malaria-related morbidity and mortality. Resistance is associated with a decrease in accumulation of drugs into the vacuole, which results from a reduced uptake of the drug, an increased efflux or a combination of both. A number of candidate genes in P. falciparum have been proposed to be involved in antimalarial resistance, each concerned in membrane transport. Weaker or stronger associations are seen in P. falciparum between the resistance to quinolines or artemisinin derivatives and codon changes in Pfmdr1, a gene which encodes Pgh-1, an ortholog of one of the P-glycoproteins expressed in multi-drug resistant human cancer cells (ABC transporter). Further analysis has revealed a new gene, Pfcrt, encoding a PfCRT protein, which resembles an anion channel. Codon changes found in the Pfcrt sequence in drug resistant isolates could facilitate the drug efflux through a putative channel. It has been proposed that the reversal of quinoline resistance by verapamil is due to hydrophobic binding to the mutated PfCRT protein. Several compounds have demonstrated in the past decade a promising capability to reverse the antimalarial drug resistance in vitro in parasite isolates, in animal models and in human malaria. These drugs belong to different pharmacological classes such as calcium channel blockers, tricyclic antidepressants, antipsychotic calmodulin antagonists, histamine H1-receptor antagonists, analgesic and antipyretic drugs, non-steroidal anti-inflammatory drugs, and to different chemical classes such as synthetic surfactants, alkaloids from plants used in traditional medicine, pyrrolidinoaminoalkanes and anthracenic derivatives. Here we summarize the progress made in biochemical and genetic basis of antimalarial resistance, emphasizing the recent developments on drugs, which interfere with trans membrane proteins involved in drug efflux or uptake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16918322     DOI: 10.2174/138945006778019372

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  19 in total

1.  Synergy of human immunodeficiency virus protease inhibitors with chloroquine against Plasmodium falciparum in vitro and Plasmodium chabaudi in vivo.

Authors:  Zhengxiang He; Li Qin; Lili Chen; Nanzheng Peng; Jianlan You; Xiaoping Chen
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

2.  In vitro activity of Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs.

Authors:  Aurélie Pascual; Maud Henry; Sébastien Briolant; Serge Charras; Eric Baret; Rémy Amalvict; Emilie Huyghues des Etages; Michel Feraud; Christophe Rogier; Bruno Pradines
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

3.  Plasmodium falciparum chloroquine resistance transporter is a H+-coupled polyspecific nutrient and drug exporter.

Authors:  Narinobu Juge; Sawako Moriyama; Takaaki Miyaji; Mamiyo Kawakami; Haruka Iwai; Tomoya Fukui; Nathan Nelson; Hiroshi Omote; Yoshinori Moriyama
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

Review 4.  Malarial hemozoin: from target to tool.

Authors:  Lorena M Coronado; Christopher T Nadovich; Carmenza Spadafora
Journal:  Biochim Biophys Acta       Date:  2014-02-17

Review 5.  Drug-resistant malaria - an insight.

Authors:  John E Hyde
Journal:  FEBS J       Date:  2007-09       Impact factor: 5.542

6.  In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.

Authors:  Victor Masseno; Steven Muriithi; Alexis Nzila
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

7.  Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.

Authors:  Jane X Kelly; Martin J Smilkstein; Roland A Cooper; Kristin D Lane; Robert A Johnson; Aaron Janowsky; Rozalia A Dodean; David J Hinrichs; Rolf Winter; Michael Riscoe
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

Review 8.  Reversed chloroquine molecules as a strategy to overcome resistance in malaria.

Authors:  David H Peyton
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

9.  Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal.

Authors:  Nathalie Wurtz; Bécaye Fall; Aurélie Pascual; Silmane Diawara; Kowry Sow; Eric Baret; Bakary Diatta; Khadidiatou B Fall; Pape S Mbaye; Fatou Fall; Yaya Diémé; Christophe Rogier; Raymond Bercion; Sébastien Briolant; Boubacar Wade; Bruno Pradines
Journal:  Malar J       Date:  2012-06-13       Impact factor: 2.979

10.  Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study.

Authors:  Bécaye Fall; Aurélie Pascual; Fatoumata D Sarr; Nathalie Wurtz; Vincent Richard; Eric Baret; Yaya Diémé; Sébastien Briolant; Raymond Bercion; Boubacar Wade; Adama Tall; Bruno Pradines
Journal:  Malar J       Date:  2013-03-20       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.